• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Revolution Medicines Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure

    6/24/25 7:05:20 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RVMD alert in real time by email
    8-K
    false 0001628171 0001628171 2025-06-23 2025-06-23 0001628171 rvmdw:CommonStock0.0001ParValuePerShareMember 2025-06-23 2025-06-23 0001628171 rvmdw:WarrantsToPurchase0.1112SharesOfCommonStockExpiring2026Member 2025-06-23 2025-06-23
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 23, 2025

     

     

    Revolution Medicines, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   001-39219   47-2029180
    (State or Other Jurisdiction
    of Incorporation)
     

    (Commission

    File Number)

      (IRS Employer
    Identification No.)

     

    700 Saginaw Drive  
    Redwood City, California   94063
    (Address of Principal Executive Offices)   (Zip Code)

    Registrant’s Telephone Number, Including Area Code: 650 481-6801

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     


    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock $0.0001 par value per share   RVMD   The Nasdaq Stock Market LLC
    Warrants to purchase 0.1112 shares of common stock expiring 2026   RVMDW   The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 1.01 Entry into a Material Definitive Agreement.

    Royalty Purchase Agreement

    On June 23, 2025 (the “Effective Date”), Revolution Medicines, Inc. (the “Company”) entered into a revenue participation right purchase and sale agreement (the “Royalty Purchase Agreement”) with Royalty Pharma Investments 2019 ICAV (“Royalty Pharma”).

    Pursuant to the Royalty Purchase Agreement, in exchange for an upfront payment of $250.0 million, Royalty Pharma purchased from the Company the right to receive tiered revenue payments (the “Royalty Payments”) with respect to worldwide net product sales (“Net Sales”) in a calendar year (“Annual Net Sales”) of (a) the Company’s RAS(ON) multi-selective inhibitor, daraxonrasib (together with certain potential future products having the same mechanism of action as daraxonrasib, collectively, “RMC-6236”) and (b) the Company’s RAS(ON) G12D-selective inhibitor, zoldonrasib (together with certain potential future products having the same mechanism of action as zoldonrasib, “RMC-9805”), if RMC-9805 is approved for the same indication or subset of the same indication for which RMC-6236 is approved (collectively, the “Royalty-Bearing Products”). In addition, under the Royalty Purchase Agreement, (i) Royalty Pharma will purchase additional Royalty Payments from the Company in exchange for a payment of $250.0 million (the “Tranche 2 Funding”), if, prior to January 1, 2028, there is a positive data readout from RASolute 302, the ongoing Phase 3 registrational trial in the second-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (“PDAC”) showing that RMC-6236 meets an agreed-upon endpoint in a statistically significant manner and the earlier of (A) the Company’s determination to proceed with the preparation and submission of a New Drug Application to the Food and Drug Administration (the “FDA”) on the basis of such readout or (B) the submission of a New Drug Application on the basis of such readout (collectively, the “Tranche 2 Trigger”) and (ii) in each case, at the Company’s election, the Company will sell and Royalty Pharma will purchase, additional Royalty Payments in exchange for (W) a payment of up to $250.0 million (the “Tranche 3 Funding”), if, prior to July 1, 2028, RMC-6236 receives FDA approval for the second-line treatment of RAS G12-mutated metastatic PDAC or metastatic PDAC, (X) a payment of up to $250.0 million (the “Tranche 4 Funding”), if the Company meets a specified Net Sales milestone for Royalty-Bearing Products prior to January 1, 2029, (Y) a payment of up to $100.0 million (the “Tranche 5 Sub Funding”), if prior to January 1, 2030, there is a positive data readout from a potential Phase 3 clinical trial for the first-line treatment of metastatic PDAC involving either (1) RMC-6236 or (2) RMC-9805, in each case, showing that the applicable Company compound meets an agreed-upon endpoint in a statistically significant manner and the FDA accepts a New Drug Application (or a supplemental application or an amendment to an existing application) on the basis of such readout, and (Z) a payment of up to the difference of (I) $250.0 million and (II) the purchase price of any Royalty Payments purchased at Tranche 5 Sub Funding (the “Tranche 5 Funding”), if prior to January 1, 2030, there is a positive data readout from a potential Phase 3 clinical trial for the first-line treatment of metastatic PDAC involving either (1) RMC-6236 or (2) RMC-9805, in each case, showing that the applicable Company compound meets an agreed-upon endpoint in a statistically significant manner.

    The table below summarizes the Royalty Payments (assuming each of the Tranche 2 Funding, the Tranche 3 Funding, the Tranche 4 Funding, the Tranche 5 Sub Funding and the Tranche 5 Fundings occurs up to the maximum amount available), based on the percentage of Annual Net Sales of the Royalty-Bearing Products.

     

    Annual

    Net Sales

       Upfront
    Royalty
        Tranche 2
    Royalty
        Tranche 3
    Royalty
        Tranche 4
    Royalty
        Tranche 5
    Sub Royalty
       

    Tranche 5

    Royalty

       Total
    Royalty
     

    $0–$2 billion 

         2.55 %      2.00 %      1.50 %      1.00 %      0.30 %    0.45% (or 0.75% if no Tranche 5 Sub Funding)      7.80 % 

    > $2 billion and ≤ $4 billion

         1.50 %      1.00 %      0.80 %      0.75 %      0.20 %    0.30% (or 0.50% if no Tranche 5 Sub Funding)      4.55 % 

    > $4 billion and ≤ $8 billion

         0.60 %      0.40 %      0.40 %      0.50 %      0.20 %    0.30% (or 0.50% if no Tranche 5 Sub Funding)      2.40 % 

    If the Company opts to sell Royalty Pharma a right to receive a portion of Annual Net Sales of the Royalty-Bearing Products that is less than the maximum permitted under the Royalty Purchase Agreement with respect to the Tranche 3 Funding, the Tranche 4 Funding, the Tranche 5 Sub Funding or the Tranche 5 Funding, then the applicable rates set forth above in respect of such Royalty Payments would be scaled down on a pro rata basis.


    Additionally, the Royalty Purchase Agreement provides for an upward adjustment to the Royalty Payment rates in the years from 2030 to 2041 in the event that Annual Net Sales in the immediate prior year are below an agreed-upon threshold. This threshold was derived from return-on-investment calculations and is in the lower end of the ranges described above. Any upward adjustment will revert to the original Royalty Payment rates in the event that Annual Net Sales are above a different agreed-upon threshold. The upward adjustment to the Royalty Payment rates applies only to the $0–$2 billion Annual Net Sales tier, and the adjusted total Royalty Payment rate for this tier remains in the single digits.

    The Royalty Payments in respect of Annual Net Sales of RMC-6236 in the United States will end 15 years after the first commercial sale of RMC-6236 in the United States. The Royalty Payments (if any) in respect of Annual Net Sales of RMC-9805 in the United States will end 15 years after the earlier to occur of (i) the date that RMC-9805 is approved in an overlapping indication with RMC-6236 in the United States and (ii) the first commercial sale of RMC-6236 in the United States. The Royalty Payments in respect of Annual Net Sales of RMC-6236 outside the United States will end 15 years after the first commercial sale of RMC-6236 in the European Union. The Royalty Payments (if any) in respect of Annual Net Sales of RMC-9805 outside the United States will end 15 years after the earlier to occur of (i) the date that RMC-9805 is approved in an overlapping indication with RMC-6236 in any country in the European Union and (ii) the first commercial sale of RMC-6236 in the European Union.

    If, prior to the achievement of the Tranche 2 Trigger, the Company enters into a definitive agreement for a change of control, the Company will have the option to cancel the Tranche 2 Funding and the associated Royalty Payments. Royalty Pharma agrees to cooperate with the transfer of the Royalty Purchase Agreement to any acquiror in connection with a change of control of the Company.

    The Royalty Purchase Agreement contains customary representations, warranties and indemnities of the Company and Royalty Pharma, and customary covenants on the part of the Company.

    Loan Agreement

    On the Effective Date, the Company also entered into a loan agreement (the “Loan Agreement” and, together with the Royalty Purchase Agreement, the “Strategic Financing Agreements”) with Wilmington Trust, National Association, as administrative agent (the “Agent”), and Royalty Pharma Development Funding, LLC, as a lender (the “Lender”).

    The Loan Agreement provides for a term loan facility of up to $750.0 million (the “Term Loan Facility”), consisting of three tranches, one of which must be drawn and the other two of which may be drawn at the Company’s option during certain commitment periods, subject to the satisfaction or waiver of certain terms and conditions: (i) a tranche in an aggregate principal amount of $250.0 million (the “Tranche A Loans” and the date on which the Tranche A Loans are funded, the “Tranche A Funding Date”), which is required to be drawn in whole in a single draw by the Company within 45 days of its receipt of marketing approval from the FDA for daraxonrasib for any indication or treatment related to metastatic PDAC, if such approval is received on or prior to January 1, 2028 unless the Company has previously elected to terminate the Term Loan Facility (as further described below); (ii) a tranche in an aggregate principal amount up to $250.0 million (the “Tranche B Loans” and the date on which the Tranche B Loans are funded, the “Tranche B Funding Date”), which the Company may elect to borrow in a single draw (in whole or in part), within 45 days of the date the Agent receives certification of the Company’s achievement of a specified Net Sales milestone, if this milestone is achieved prior to January 1, 2028; and (iii) a tranche in an aggregate principal amount up to $250.0 million (the “Tranche C Loans” and, together with the Tranche A Loans and the Tranche B Loans, the “Term Loans” and the date on which the Tranche C Loans are funded, and, together with the Tranche A Funding Date and the Tranche B Funding Date, each, a “Funding Date”), which the Company may elect to borrow in a single draw (in whole or in part), within 45 days of the date the Agent receives certification of the Company’s achievement of a specified Net Sales milestone, if this milestone is achieved prior to January 1, 2028.

    The Term Loan Facility matures on the earlier of (i) the six year anniversary of the Tranche A Funding Date and (ii) December 31, 2032 (such earlier date, the “Maturity Date”), and the Term Loans thereunder bear interest at a floating per annum rate equal to (a) the three-month term SOFR (subject to a 3.50% floor) plus (b) 5.75%, payable on a quarterly basis. The Term Loan Facility has no scheduled amortization payments prior to the Maturity Date.


    On each Funding Date, the Company is required to pay the Lender an upfront fee equal to 2.00% of the Term Loans drawn on such Funding Date. In addition, the Loan Agreement requires the Company to make prepayments in the event of a change of control and permits the Company to make voluntary prepayments in whole. Principal prepayments in respect of the Term Loans will be subject to, with respect to each tranche of the Term Loans, (i) prior to the second anniversary of the Funding Date of such tranche of Term Loans, a make-whole premium in an amount equal to the sum of all interest that would have accrued and been payable from such prepayment date to (but excluding) such second anniversary plus (ii) a prepayment premium equal to either (a) 3.00% of such tranche of Term Loans, for prepayments prior to the third anniversary of the Funding Date of such tranche of Term Loans or (b) 1.00% of such tranche of Term Loans, for prepayments on or after the third anniversary of the Funding Date of such tranche of Term Loans. For the avoidance of doubt, no make-whole premium or prepayment premium shall be due and payable if the Term Loans are repaid on the Maturity Date.

    Should a change of control of the Company occur prior to the Tranche A Funding Date, or the Company elects to terminate the Term Loan Facility prior to the Tranche A Funding Date, the Company is required to pay the Lender a sum equal to: (i) 1.00% of the Tranche A Loans, plus (ii) the make-whole premium and prepayment premium with respect to the Tranche A Loans, calculated as if the full amount of the Tranche A Loans were drawn on the date on which the change in control was consummated or the date the Company elected to terminate the Term Loan Facility, as applicable. If the Company does not draw the Tranche A Loans within 45 days of its receipt of marketing approval from the FDA for daraxonrasib for any indication or treatment related to metastatic PDAC, then the Company will be required to pay the Lender a sum equal to: (i) 1.00% of the Tranche A Loans, plus (ii) the make-whole premium and prepayment premium with respect to the Tranche A Loans, calculated as if the full amount of the Tranche A Loans were drawn on the 45th day following its receipt of such FDA approval.

    The Term Loan Facility will be guaranteed by certain of the Company’s existing and future subsidiaries (collectively, the “Guarantors”), and the obligations of the Company and the Guarantors under the Term Loan Facility will be secured by security interests in, and pledges over, substantially all of the assets of the Company and the Guarantors (including, without limitation, capital stock, material bank accounts and intercompany receivables), in each case, subject to certain agreed security principles, permitted liens and other customary exceptions and qualifications.

    The Loan Agreement contains customary covenants that limit the Company’s and its subsidiaries’ ability to, among other activities (but subject to certain customary exceptions): (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt; (iii) transfer or sell assets; (iv) create liens; (v) engage in certain transactions with affiliates; (vi) create restrictions on dividends or other payments by the Company’s subsidiaries; and (vii) merge, consolidate or effect other fundamental changes. The Loan Agreement does not include any financial covenants. The Loan Agreement also includes certain customary affirmative covenants, including financial reporting, notice obligations, and requirements to grant and provide guarantees and securities interest in respect of property and assets acquired from time to time after the Effective Date.

    The Loan Agreement provides an enumerated list of customary events of default, including, without limitation, payment defaults, breach of representations and warranties, covenant defaults, cross-defaults to certain material agreements and certain indebtedness, certain events of bankruptcy, material judgments, and the occurrence of a material adverse change. If an event of default occurs under the Loan Agreement, the Agent, for and on behalf of the Lender, will be entitled to exercise remedial rights and powers and take various actions (including, without limitation, (i) the acceleration of all amounts due under the Term Loan Facility; (ii) the application of default rate interest; (iii) the exercise of powers of attorney, voting proxies and other similar rights; (iv) the foreclosure and sale of property and assets and (v) other actions permitted to be taken by a secured creditor).

    The foregoing descriptions of the Strategic Financing Agreements do not purport to be complete and are qualified in their entirety by reference to such agreements, copies of which the Company expects to file, with certain confidential terms redacted, as exhibits to its Quarterly Report on Form 10-Q for the quarter ending June 30, 2025.

     


    Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

    The information set forth under Item 1.01 above is incorporated by reference into this Item 2.03.

    Item 7.01 Financial Statements and Exhibits.

    Press Release

    On June 24, 2025, the Company issued a press release announcing the Strategic Financing Agreements, a copy of which is furnished as Exhibit 99.1 to this report.

    Supplemental Financial Information

    As a result of entering into the transactions described in Item 1.01 of this report, the Company is removing its cash runway end date guidance.

    With respect to 2025 GAAP net loss guidance, the Company is in the process of evaluating the appropriate accounting treatment of the facility described in this report and also evaluating the impact of the decision to pursue independent global development and commercialization. Accordingly, the Company is withdrawing its previous guidance on expected 2025 GAAP net loss and expects to provide updated financial guidance in the Company’s second quarter 2025 earnings release.

    The information furnished under this Item 7.01 and in the accompanying Exhibit 99.1 to this report shall be deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933 (the “Securities Act”), and shall not be incorporated by reference into any filing made by the Company with the Securities and Exchange Commission (the “SEC”) under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

    Cautionary Statement Regarding Forward-Looking Statements

    This report includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements made in this report that are not historical facts may be considered forward-looking statements, including, without limitation, statements regarding the Strategic Financing Agreements (including with respect to potential trigger events, tranche loans and royalty payments), and the Company’s decision to pursue independent global development and commercialization. Forward-looking statements are typically, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “expect,” and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause the Company’s development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including the Company’s programs’ current stage of development, the process of designing and conducting preclinical and clinical trials, risks that the results of prior clinical trials may not be predictive of future clinical trials, clinical efficacy, or other future results, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the Company’s ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of the Company’s capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape, and the effects on the Company’s business of the global events, such as international conflicts or global pandemics. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of the Company in general, see the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 7, 2025, and its future periodic reports to be filed with the SEC. Except as required by law, the Company undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

     


    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit
    No.

      

    Description

    99.1    Press Release, dated June 24, 2025.
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        REVOLUTION MEDICINES, INC.
    Date: June 24, 2025     By:  

    /s/ Mark A. Goldsmith

         

    Mark A. Goldsmith, M.D., Ph.D.

    President and Chief Executive Officer

    Get the next $RVMD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $RVMD

    DatePrice TargetRatingAnalyst
    7/16/2024$46.00 → $62.00Buy
    Needham
    7/12/2024$52.00Overweight
    Barclays
    7/8/2024$63.00Buy
    Jefferies
    4/12/2024$36.00 → $46.00Buy
    Needham
    4/10/2024$36.00 → $48.00Outperform → Strong Buy
    Raymond James
    3/11/2024$43.00Overweight
    Piper Sandler
    1/5/2024$31.00 → $34.00Neutral → Buy
    BofA Securities
    1/4/2024$41.00Outperform
    Wedbush
    More analyst ratings

    $RVMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Schroeder Thilo bought $59,999,962 worth of shares (1,304,347 units at $46.00) (SEC Form 4)

      4 - Revolution Medicines, Inc. (0001628171) (Issuer)

      12/9/24 4:15:16 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RVMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Goldsmith Mark A exercised 37,000 shares at a strike of $0.54, increasing direct ownership by 9% to 465,720 units (SEC Form 4)

      4 - Revolution Medicines, Inc. (0001628171) (Issuer)

      7/2/25 4:11:45 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Horning Sandra was granted 3,142 shares, increasing direct ownership by 3% to 96,574 units (SEC Form 4)

      4 - Revolution Medicines, Inc. (0001628171) (Issuer)

      6/30/25 4:27:49 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Patel Sushil was granted 3,142 shares, increasing direct ownership by 16% to 23,090 units (SEC Form 4)

      4 - Revolution Medicines, Inc. (0001628171) (Issuer)

      6/30/25 4:27:19 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RVMD
    SEC Filings

    See more
    • SEC Form 8-K filed by Revolution Medicines Inc.

      8-K - Revolution Medicines, Inc. (0001628171) (Filer)

      6/27/25 4:05:55 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure

      8-K - Revolution Medicines, Inc. (0001628171) (Filer)

      6/24/25 7:05:20 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Revolution Medicines Inc.

      8-K - Revolution Medicines, Inc. (0001628171) (Filer)

      6/18/25 4:23:13 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RVMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Needham reiterated coverage on Revolution Medicines with a new price target

      Needham reiterated coverage of Revolution Medicines with a rating of Buy and set a new price target of $62.00 from $46.00 previously

      7/16/24 8:15:42 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Barclays initiated coverage on Revolution Medicines with a new price target

      Barclays initiated coverage of Revolution Medicines with a rating of Overweight and set a new price target of $52.00

      7/12/24 7:33:26 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jefferies initiated coverage on Revolution Medicines with a new price target

      Jefferies initiated coverage of Revolution Medicines with a rating of Buy and set a new price target of $63.00

      7/8/24 8:13:53 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RVMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

      Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers and Summit Therapeutics Inc. (NASDAQ:SMMT), a biopharmaceutical oncology company focused on patient-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs, today announced the companies have entered into a clinical collaboration in multiple solid tumor settings to evaluate the safety and efficacy of each of Revolution Medicines' clinical-stage RAS(ON) inhibitors, including the multi-selective inhibitor daraxonrasib (RMC-6236), G12D-selective inhibitor zoldo

      6/30/25 8:00:00 AM ET
      $RVMD
      $SMMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors

      REDWOOD CITY, Calif. and MIAMI, June 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers and Summit Therapeutics, Inc. (NASDAQ:SMMT), a biopharmaceutical oncology company focused on patient-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs, today announced the companies have entered into a clinical collaboration in multiple solid tumor settings to evaluate the safety and efficacy of each of Revolution Medicines' clinical-stage RAS(ON) inhibitors, including the multi-selecti

      6/30/25 8:00:00 AM ET
      $RVMD
      $SMMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers

      Flexible funding provides $2 billion in committed capital comprised of up to $1.25 billion of synthetic royalty and up to $750 million in corporate debtCompany moving forward with independent global commercialization strategy to prioritize patient reach and maximize shareholder valueTransaction expands Revolution Medicines' financial resources and optionality with $1.25 billion of the $2 billion available at the company's discretionRevolution Medicines to host webcast today at 8:00 a.m. Eastern Time REDWOOD CITY, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-add

      6/24/25 7:00:00 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RVMD
    Financials

    Live finance-specific insights

    See more
    • Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress

      Strong execution of two ongoing Phase 3 trials of daraxonrasib; company expects to substantially complete enrollment of RASolute 302 in patients with pancreatic cancer this yearNew non-small cell lung cancer clinical data from RAS(ON) inhibitor portfolio support strategies for first-line metastatic and earlier lines of treatmentAnthony Mancini joins as chief global commercialization officerRevolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial

      5/7/25 4:02:00 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025

      REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter of 2025 on Wednesday, May 7, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live web

      4/30/25 4:05:00 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

      Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer to enable expected data readout in 2026Company is activating study sites for Phase 3 RASolve 301 trial of daraxonrasib in previously treated locally advanced or metastatic RAS mutant non-small cell lung cancerCompany anticipates initiating two additional registrational trials of daraxonrasib in earlier lines of treatment for pancreatic cancer in the second half of 2025Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NA

      2/26/25 4:02:00 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RVMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Revolution Medicines Inc.

      SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

      11/8/24 10:52:39 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Revolution Medicines Inc. (Amendment)

      SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

      2/14/24 6:30:27 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Revolution Medicines Inc. (Amendment)

      SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

      2/14/24 9:26:21 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RVMD
    Leadership Updates

    Live Leadership Updates

    See more
    • Circle Pharma Appoints Stephen Kelsey, MB ChB, MD, to its Board of Directors

      Circle Pharma, a company focused on developing macrocycle therapeutics against targets previously considered to be undruggable, has appointed Stephen Kelsey as an independent member of its Board of Directors. Dr. Kelsey has extensive experience in oncology clinical development. He currently serves as president, head of research and development and chief medical officer at Revolution Medicines (NASDAQ:RVMD), and previously held roles including president of Onkaido Therapeutics, the oncology-focused unit of Moderna (NASDAQ:MRNA), senior vice president of new products at Medivation (acquired by Pfizer (NYSE: PFE)), executive vice president and chief medical officer at Geron Corporation (NASDAQ

      12/15/22 7:00:00 AM ET
      $GERN
      $MRNA
      $PFE
      $RVMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Revolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors

      REDWOOD CITY, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the appointment of Lorence Kim, M.D., to its board of directors. Dr. Kim has made significant contributions across the biotechnology and financial industries during his career at Moderna and Goldman Sachs. He has extensive operational expertise and an extraordinary track record in raising capital for high-growth health care companies. Dr. Kim will serve as an independent director for the remaining term of Neil Exter, who is stepping down after serving as a director most recently since 2019

      7/13/22 7:00:00 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care